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Abstract
Background: GPR17 is a hybrid G-protein-coupled receptor (GPCR) activated by two unrelated ligand families,
extracellular nucleotides and cysteinyl-leukotrienes (cysteinyl-LTs), and involved in brain damage and repair. Its
exploitment as a target for novel neuro-reparative strategies depends on the elucidation of the molecular
determinants driving binding of purinergic and leukotrienic ligands. Here, we applied docking and molecular
dynamics simulations (MD) to analyse the binding and the forced unbinding of two GPR17 ligands (the
endogenous purinergic agonist UDP and the leukotriene receptor antagonist pranlukast from both the wild-type
(WT) receptor and a mutant model, where a basic residue hypothesized to be crucial for nucleotide binding had
been mutated (R255I) to Ile.
Results: MD suggested that GPR17 nucleotide binding pocket is enclosed between the helical bundle and
extracellular loop (EL) 2. The driving interaction involves R255 and the UDP phosphate moiety. To support this
hypothesis, steered MD experiments showed that the energy required to unbind UDP is higher for the WT
receptor than for R255I. Three potential binding sites for pranlukast where instead found and analysed. In one of
its preferential docking conformations, pranlukast tetrazole group is close to R255 and phenyl rings are placed into
a subpocket highly conserved among GPCRs. Pulling forces developed to break polar and aromatic interactions of
pranlukast were comparable. No differences between the WT receptor and the R255I receptor were found for the
unbinding of pranlukast.
Conclusions: These data thus suggest that, in contrast to which has been hypothesized for nucleotides, the lack of
the R255 residue doesn’t affect the binding of pranlukast a crucial role for R255 in binding of nucleotides to
GPR17. Aromatic interactions are instead likely to play a predominant role in the recognition of pranlukast,
suggesting that two different binding subsites are present on GPR17.
Background
Extracellular adenine and uracil nucleotides (e.g., ATP,
ADP, UTP, UDP and sugar nucleotides) are signaling
molecules involved in several patho physiological phe-
nomena, from short-term signaling (neurotransmission,
mechanosensory transduction, secretion and vasodilata-
tion) to long-term functions (proliferation, differentia-
tion, survival and death, development and post-injury
repair) [1]. Conversely, cysteinyl-leukotrienes (cysteinyl-
LTs) are inflammatory lipid mediators derived from ara-
chidonic acid through the 5-lypoxigenase (5-LO)
pathway, and are implicated in bronchial asthma, stroke
and cardiovascular diseases [2]. Despite the fact that
nucleotides and cysteinyl-LTs originate from totally
independent metabolic pathways, several data suggest
important functional interactions between two families
of signaling molecules and their receptors. To date,
eight distinct nucleotide G-protein-coupled receptors
(GPCRs), the P2Y receptors have been identified
(P2Y1;2;4;6;11;12;13;14) and classified in two distinct phylo-
genetic subgroups: the first subgroup includes the
P2Y1;2;4;6;11 subtypes, whereas P2Y12,P 2 Y 13 and P2Y14
belong to the second subgroup [3]. Only two cysteinyl-
LTs responding GPCRs (the CysLT1 and CysLT2 recep-
tors) are instead currently recognized. However, certain
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explained by interaction with either CysLT1 or CysLT2,
raising the possibility of the existence of additional
CysLT receptors [4-7]. There exists a functional cross-
talk between the P2Y and CysLT receptor families, since
both nucleotides and cysteinyl-LTs massively accumu-
late at sites of inflammation and both types of receptors
are co-expressed in the same peripheral inflammatory
cells. This evidence shows a cross-regulated response
typical of the chemoattractant systems [8]. Along this
line, in rat brain microglial cells, both nucleotides and
cysteinyl-LTs, that are co-released as a consequence of
the activation of P2Y1 and CysLT receptors, contribute
to neuroinflammation and neurodegeneration [9].
Nucleotides can also regulate, via heterologous desensi-
tization, CysLT1 receptor activity [8] and, in parallel,
the CysLT1 receptor antagonists pranlukast and monte-
lukast can functionally influence P2Y receptor signaling
pathways in human monocyte/macrophage-like cells
[10]. In addition, P2Y12 was found to be promiscuously
activated by both nucleotides and LTE4 [11], further
underlying the close relationship between the two
families. Both P2Y and CysLT receptors share the typi-
cal seven-transmembrane spanning topology of GPCRs.
Besides their heterogeneity in function and tissue distri-
bution, P2Y and CysLT receptors share a phylogenetic
relationship, given that both families, together with
GPR17 and other related receptors, belong to the so
called “purine receptor cluster” of GPCRs [12]. This
cluster also includes several “orphan” receptors respond-
ing to yet-unidentified endogenous ligands. Among
these, the orphan receptor GPR17 appeared to us as a
possible common ancestral progenitor that originated
the two above receptor families. On this basis, we
recently cloned the human, rat and mouse GPR17 and
demonstrated that they all respond to both nucleotides
and cysteinyl-LTs [13,14].
Thus, GPR17 is a hybrid receptor linking the P2Y and
the CysLT receptor families. Besides endogenous ligands,
synthetic compounds typical of the two above receptor
families are also active at GPR17. Specifically, it has been
shown that GPR17 can be activated in vitro by uracil
nucleotides (UDP and UDP-sugars) and by cysteinyl-LTs
(LTC4,L T D 4 and LTE4). GPR17 activation can be
contrasted by treatment with two well known P2Y
antagonists, MRS2179 (2’-deoxy-N6-methyladenosine
3’,5’-biphosphate) and cangrelor (N(6)-(2-methyl-
thioethyl)-2-(3,3,3-trifluoropropylthio)-b, g-dichloro-
methylene-ATP), and also by the already marketed
CysLT receptor antagonists pranlukast (N-[4-oxo-2-(2H-
tetrazol-5-yl) chromen-7-yl]-4-(4-phenylbutoxy)
benzamide) and montelukast (2-[1-[[(1R)-1-[3-[2-(7-
chloroquinolin-2-yl) ethenyl] phenyl]-3-[2-(2-hydroxy-
propan-2-yl) phenyl] propyl] sulfanylmethyl]cyclopropyl]
acetic acid). Furthermore, in a model of focal rodent
brain ischemia, its in vivo early knock down with either
pharmacological or specific antisense strategies, reduces
the progression of cerebral ischemic damage, highlighting
GPR17 as novel therapeutic target for ischemia [13].
Since at present this disease still remains without a speci-
fic pharmacological treatment, molecules active as
GPR17 inhibitors may represent a new class of promising
anti-ischemic agents. On the other hand, more recent
data has shown that GPR17 indeed has a dual and spatio-
temporal-dependent role in the development and post-
injury repair of damage in the brain and in spinal cord.
While at very early times after injury, GPR17 seems to
mediate cell death, at later stages, GPR17 may even parti-
cipate to repair mechanisms [14,15]. Thus, GPR17 may
be proposed as a “sensor” of damage that is activated by
the specific signaling molecules (uracil nucleotides and
cysteinyl-LTs) that are released at high levels in the
lesioned area, and as a new target for amyelinating post-
injury responses. These data further highlight the attrac-
tivity of this receptor as a new target for drug discovery.
Recently, results obtained in recombinant systems,
have been proposed GPR17 as a constitutive ligand-
independent negative regulator of the CysLT1 receptor,
that modulates CysLT1-mediated functions at the cell
membrane [16]. Although this interesting hypothesis
will have to be confirmed in vivo, it may be hypothe-
sized that GPR17 may function as both a ligand-depen-
dent and independent receptor depending upon specific
patho-physiological conditions. Definitely, to fully
understand the therapeutic potential of GPR17, specific
ligands that do not interfere with the other P2Y or
CysLT receptors are needed.
Along this line, as a first step to the design of selective
ligands, we have recently provided a computational
study of GPR17, providing a macroscopic view of a
three-dimensional (3D) model of GPR17 complexed
with three representative purinergic compounds: the
endogenous agonist UDP and the synthetic antagonists
MRS2179 and cangrelor [17]. To do so, we used a raw
homology model of GPR17, based on the X-ray crystal-
lographic 3D structure of bovine rhodopsin (bRh) 1U19,
deposited at RCSB Protein Data Bank http://www.pdb.
org, the best high-resolution 3D template for a mamma-
lian GPCRs that was then available [18]. In fact, for
many years, the crystalline structure of the inactive
receptor form of bRh has been widely used as a tem-
plate, even for significantly distant receptors, on the
basis of the commonly accepted assumption that, in
evolutionary related proteins, the 3D structure is more
conserved than the amino acid sequence. Fortunately,
within the GPCRs superfamily, one of the essential
determinant for GPCRs activity concerns the 7TM
architecture that is well conserved between all GPCRs.
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subsequent structure-based drug discovery approach are
widely accepted, since experimental data have indeed
confirmed computational predictions for many GPCR
models [19-21]. Recently, thanks to protein engineering,
the modified structures of two human GPCRs have been
solved, providing new templates suitable for homology
modeling: the adenosine A2A receptor (A2AR) bound to
the high-affinity antagonist ZM241385 (PDB code
3EML) [22]; the b2-adrenergic receptor-Fab (b2AR-Fab)
(PDB code 2R4R) [23] and the b2-adrenergic receptor-
T4 (b2AR-T4) (PDB code 2RH1) [24,25], both bound to
their inverse agonist carazolol; the mutated b2-adrener-
gic receptor-(E122W)-T4 (b2AR(E122W)-T4) (PDB code
3D4S) bound to cholesterol and its partial inverse ago-
nist timolol [26]. In addition, the crystal structure of the
turkey b1-adrenergic receptor (b1AR, PDB code 2VT4),
in complex with the high-affinity antagonist cyanopindo-
lol, has been also solved [27], raising the issue of how a
range of compounds with very different affinity values
can bind to such closely related receptor subtypes.
Finally, also the squid Rh (PDB code 2Z73) [28] has
been determined. Analysis of the newly published crystal
structures of the squid Rh, the human b2AR, the turkey
b1AR and the A2ARf u r t h e rc o n f i r mt h a tt h eT M 7c o r e
is conserved among the entire GPCR superfamily.
Nevertheless, structural differences have been found
even within the TM bundle. Comparison between bRh
and b2AR structures shows that the binding site of the
ligand carazolol on b2AR is very similar to that of retinal
on rhodopsin, despite the fact that carazolol is a diffusi-
ble ligand rather than a covalently-bound ligand like ret-
inal. In contrast to the b-adrenergic ligands and retinal,
the A2AR antagonist ZM241385, exhibits a significantly
different orientation within the TM bundle. Interest-
ingly, the bound A2AR ligand, while interacting with
helices, gets in contact also with EL2 and EL3. The pub-
lication of such new structures allows a very detailed
assessment on the reliability of models based only on
ground state the bRh: this is a unique GPCR, because of
its light-induced activation mechanism driven by the
cis/trans isomerization of its covalently-bound ligand.
However, its structure has been solved with high resolu-
tion, in different crystallization environment, in different
states and both with different methodologies (NMR and
X-ray). In fact, a detailed analysis of the structure differ-
ences connected to crystal packing and binding states
reveals that, in spite of the close similarity to the bRh
general architecture, mutual rearrangement of the
helices involved in the activation mechanism are
observed. Recently, also the crystal structure of the
native retinal-free GPCR bovine opsin (bOps) has been
solved [29]: the breakage of the so-called ionic lock
restraints the helical pack in the resting structure and
allows a rotation along the axes of the helical bundle
[30]. In our previous study, we utilized the rhodopsin-
based model of GPR17, with or without ligands, and
embedded in fully hydrated phospholipid bilayer. This
model was then refined by means of docking combined
with molecular mechanics (MM) and molecular
dynamics techniques (MD). Our MD simulations on the
rhodopsin-based model of GPR17 suggested that the
primary nucleotide binding pocket in GPR17 is con-
tained in an accessible crevice enclosed between trans-
membrane (TM) helices (mainly TM3, TM5, TM6 and
TM7) and extracellular loop (EL) 2, in general agree-
ment with the binding site proposed for small molecules
to other class A rhodopsin-like GPCRs and for nucleo-
tides to already known P2Y receptors [31-33]. Based on
our computational data, we also hypothesized that at
the extracellular interface of the receptor, the N-termi-
nus (Nt) region and EL2 and EL3 form accessory bind-
ing surfaces that could address ligands to the deeper
main binding pocket. We finally proposed that the driv-
ing force for binding of nucleotides to GPR17 was the
electrostatic interaction between the phosphate groups
of incoming ligand and the basic arginine residue at
position 6.55 (See Ballesteros and Weinstein’sn u m b e r -
ing system for residues index [34]) that was a recurrent
target for all the nucleotidic ligands docked in our
GPR17 model. This residue belongs to the conserved
motif H-X-X-R/K typical of all the related P2Y and
CysLT receptors; this motif is commonly believed to be
a key extracellular recognition for nucleotides since
1995, when the first hypothesis on nucleotides binding
mode on P2Y1 was formulated [35-40]. The overall con-
figuration of the identified binding pocket shares com-
mon features with the ones described for the P2Y
receptors [33,41], albeit showing some interesting
differences.
For the P2Y receptors, it’s today commonly accepted
that the driving force attracting nucleotides is provided
by a triplet of conserved positively charged residues,
b u r i e di nt h eT Mb u n d l eo ft h er e c e p t o r s :t h e s ea r e
believed to interact with the negative charges of the
phosphate groups of nucleotides [35-37]. For the P2Y1-
subgroup, residues R3.29 (TM3), R/K6.55 (TM6) and
R7.39 (TM7) have been proposed to be critical for
nucleotide recognition. Between the three residues, only
6.55 is conserved as a basic one among all the P2Y
receptor family members, and belongs to H-X-X-R/K
motif cited above, whereas R3.29 and R7.39 are only
typical of the P2Y1-subgroup. The last residue belongs
to the Y-Q/K-X-X-R motif in TM7 and is shared by
P2Y1,P 2 Y 2,P 2 Y 4,P 2 Y 6 and P2Y11 [3,42]. In the P2Y12-
subgroup, it was proposed that two lysines, one located
in EL2 (immediately before the cysteine residue involved
in the formation of the conserved disulphide bridge),
Parravicini et al. BMC Structural Biology 2010, 10:8
http://www.biomedcentral.com/1472-6807/10/8
Page 3 of 18and the other one located in TM7 at position 7.35
(belonging to the K-E-X-X-L motif conserved among
P2Y12, P2Y13, and P2Y14), can account for cationic coor-
dination of the phosphate moiety instead of residues
R3.29 and R7.39. Furthermore, the residue close to the
conserved cysteine in EL2 appears to be involved in
interactions with the phosphates also for the the P2Y1-
like receptors [33,41]. More recently, a variant of this
model has been proposed for P2Y14, where two of the
basic residues (6.55 and 7.35) are instead assumed to
bind the hexose moiety of sugar-nucleotides [43]. Inter-
estingly, multiple sequence alignment of GPR17 with
P2Y family members showed that GPR17 lacks the basic
triplet and the residue 6.55 binding the phosphates is
the only one conserved in the putative pocket [17],
despite the many positively charged amino acids typical
of this peculiar receptor. We also found that the binding
pocket appears to be shared by both nucleotide agonists
and antagonists, even if the modality of binding differs
in some details, highlighting a heterogeneity in the bind-
ing pocket recently arisen also within the P2Y receptor
family.
Unfortunately, no definitive 3D model of any CysLT
receptors complexed with their ligands has been pro-
posed yet; so, a convincing hypothesis on the basis of
recognition is currently unavailable, despite several anti-
leukotriene agents are already available in the market
and others have already successfully started their track
in drug development trials. In this respect, the CysLT1
receptor antagonist zafirlukast (Accolate) was the first
CysLT receptor antagonist to be marketed in the USA;
montelukast (Singulair) has been introduced to market
since 1998 in the treatment of asthma and allergic rhini-
tis [44]; pranlukast is still waiting for a global extension
of its commercialization and it is currently available
only in Japan [7,45,46].
In the present paper, to get more insight into the role
of residues suggested to be crucial for the recognition
mechanism by our previous computational data, the
basic residue R6.55 of our GPR17 wild-type (WT) recep-
tor model has been mutated to isoleucine, giving a
mutant (R255I) receptor model of GPR17. The effects of
this mutation on recognition nucleotides have been stu-
died in silico, by simulating the “unbinding processes” of
two docked ligands (the endogenous purinergic agonist
the UDP and the leukotriene receptor antagonist pranlu-
k a s t )f r o mb o t ht h ew i l d - t y p e( W T )a n dt h em u t a n t
(R255I) receptor model of GPR17 using steered MD
(SMD) simulations. The comparison between the two
simulations clearly shows that the energy required to
force the unbinding of UDP from the WT receptor
model was significantly higher than the work spent for
the unbinding of the ligand from the R255I receptor.
These data suggest that the same target residue (R255)
could play a different role in either the recognition of
distinct classes of ligands or in the modulation of recep-
tor’s activity when activated by ligands. Although the in
silico hypothesis presented here still has to be confirmed
experimentally, it represents an interesting starting point
for in vitro validation. For example, according to our
computational hypothesis, the actual involvement of the
residue R6.55 in recognition of nucleotide phosphates
has been also confirmed by experimental data recently
produced by our group. Using a frontal affinity chroma-
tographic-based method coupled to a mass spectrometry
detection (FAC-MS), we evaluated the elution time of
UDP and other nucleotide-derivative ligands on two
chromatographic columns where cell membrane expres-
sing both the native and the mutated form of GPR17
were entrapped on the surface of the stationary phase.
For the natural agonist UDP, we found that the reten-
tion time on the WT receptor-containing column was
higher than for the mutate receptor-containing column,
suggesting that the lack of R255 may reduce the affinity
for this ligand (unpublished data). In the present paper,
we report the results obtained by applying the same
computational approach to simulate the forced unbind-
ing of the leukotriene receptor antagonist pranlukast, in
order to investigate if the mutation affects the binding
of pranlukast and if the putative target R255 is shared
by the two molecules. At present, the study of the
unbinding processes at atomic scale is available with the
use of atomic force microscopy (AFM) [47], where
external forces are applied to molecules to probe their
mechanical resistance. The virtual mimics of such
experiments are provided by steered MD (SMD) and
constant force MD (CFMD), that mimic the so-called
force-ramp and the force-clamp methods used in AFM,
respectively. In the force-ramp method the mechanical
resistance of biomolecules is measured applying a time-
dependent force [48], while in the force-clamp methods
a constant force is used [49]. With the use of such
external forces, the MD path becomes irreversible and
gives access to processes involving non-covalent bonds
that cannot be achieved in the same time scale with the
conventional MD simulations [50]. Based on SMD/
CFMD, several reliable predictions of binding/unbinding
[51-58] and folding/unfolding [59-65] processes have
been obtained for various biological complexes. In
unbinding experiments, the analysis of the interactions
of dissociating ligands and the evolution of applied
forces and ligand positions provide qualitative informa-
tion about the irreversible work spent in the unbinding
process: in this way, insights in structural features of
receptor-ligand complexes and possible binding path-
ways are gained. However, our propose here was not to
use SMD to define the exact ligand unbinding pathway/
mechanisms, an issue that would require a more
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elucidate the role of R255 as possible target for GPR17
ligands. In fact, the simulations of the unbinding of
ligands, such as UDP and pranlukast, from GPR17
receptor models presented here can also provide some
attractive hypothesis on the unknown recognition
mechanism and could thus be helpful to the planning of
experimental mutagenesis studies and ligand affinity
measurements.
Results and Discussion
Comparison between GPR17 and new templates
Our MD simulations study was performed on a bRh-
based homology model of GPR17 [17], for consistency
with our previous study on GPR17, starting from a
highly refined structure of the receptor. Nevertheless,
recently, new GPCR structures have been solved and
become available for comparative modeling (see Intro-
duction). However, between the sequences of the cur-
rently available GPCR structures, for GPR17 the best
alignment score was obtained with bRh (19.3 for bRh;
15.7 for human b2AR, 15.3 for turkey b1AR and 14.3 for
human A2AR, Moe’s alignment tool) that indeed still
r e s u l t sa sag o o dc o m p r o m i s ef o rm o d e l i n gG P R 1 7
despite the lack on structural information on this recep-
tor. To assure that the topology that we found for
GPR17 was not an artefact due to the template, and also
to assess if it was still reliable in view of the new GPCR
structures, we compared our model with the structure
of the human A2AR, the three structures of the human
b2AR and the structure of the turkey b1AR. Both the
structures of human A2AR, human b2AR and turkey
b1AR showed the a-helical 7TM domain typical of the
GPCR receptor family. Superimposition of the C-a
atoms of the A2AR, the b2AR-Fab, the b2AR-T4, the
b2AR(E122W)-T4 and the b1-AR to GPR17 and to bRh
is reported in Table 1. RMSD values obtained by rigidly
superimposing the three structures to the GPR17 model
vary from 1.955 to 2.867 Å, a range which is not signifi-
cantly different from that obtained by superimposition
of the same structures to bRh.
Globally, the helical pack was highly conserved among all
the structures, and also the alignment of the a-helical
domains to the GPR17 bundle yielded a good fit, as shown
in Figure 1. In spite of the overall good fit among struc-
t u r e s ,t h e r ew e r es o m ed i f f e r e n c e si nt h eh e l i c a l
rearrangement concerning mainly TM1. In both b2AR and
b1AR structures, this domain exhibited a kink correspond-
ing to a hydrophobic motif (L-I-V-L-A-I-V) encompassing
two helical turns that caused a marked outlying exposure
of the N-terminus end of the helix: this hasn’t been found
either in our GPR17 model or in bRh. Interestingly, all the
available b-AR structures reveal the presence of an unex-
pected a-helix domain on the EL2, that is indeed signifi-
cantly different from the b-hairpin organization that has
been found for the EL2 of bRh, suggesting that this feature
could be a requirement for the binding of reversible
ligands, and that a different accessibility to the binding
pocket could exist among GPCRs [27]. Moreover, the
A2AR structure reveals substantial differences in the archi-
tecture of the extracellular domains with respect to the
other solved GPCR structures, as the EL2 is spatially con-
strained by two extra disulphide bridges that link this loop
to EL1. At this time, we don’t have any structural informa-
tions about the macroscopic arrangement of EL2 and of
the other extracellular loops in GPCRs but, being the TM
bundle so well conserved during evolution, it is reasonable
to assume that at least some of the keys for selectivity
reside in the extracellular region. This feature can also
account for the exceptional plasticity of GPCRs and their
capability to bind such a heterogeneous spectrum of
molecules.
Table 1 Alignment among GPR17 model and X-ray
templates of GPCRs
RMSD (Å) after alignment of a-helical carbon
3EML 2R4R 2RH1 3D4S 2VT4
GPR17 2.867 2.458 2.688 2.738 2.413
bRh 1.955 2.210 2.362 2.277 2.862
Figure 1 Superimposition of a-helical domains of the b2 AR-
Fab, b2 AR-T4, b2AR(E122W)-T4 b1 AR and A2A R structures to
GPR17 model. Ribbon representation of the b2AR-Fab (2R4R), b2AR-
T4 (2RH1), b2AR(E122W)-T4 (3D4S), b1AR (2VT4) and A2AR structures
after alignment of the a-helical domains to GPR17 model (in gray)
are reported in cyan, orange, green, magenta and yellow
respectively.
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MD simulations of the WT model of GPR17 complexed
with the receptor antagonist pranlukast have been per-
formed, starting from the best docking configurations of
pranlukast in its presumptive pockets. Docking studies,
combined with MD simulations, unveiled three different
potential binding sites for the antagonist pranlukast. In
these pockets, pranlukast assumed three different con-
figurations (CI, CII and CIII); all of them showed com-
parable docking energy and appeared realistic as
hypothetical binding configurations to GPR17. Globally,
these multiple binding modes are not surprising,
because they account for the many degrees of freedom
of pranlukast. The conformational analysis of the mole-
c u l e sg i v er i s et om a n ys t a b l ec o n f o r m a t i o n sw h i c ha r e
very close in internal energy; hence the molecule can
accommodate into the binding pocket with different fea-
tures. These findings also suggest that the receptor can
assume slightly different conformations and that the
activation process may occur in a multi-step mechan-
ism, where important conformational changes sequen-
tially take place. The overall pictures of the antagonist-
receptor complexes extracted from the 6 ns of MD runs
are showed in Figure 2. We then computed the total
energy of the system and the root mean square devia-
tion (RMSD) for the MD trajectory of each of the three
pranlukast configurations. Figure 3 and Figure 4a show,
respectively, the energetic profile and the RMSD of C-a
of the three pranlukast-GPR17 complexes, as a function
of time. Both the total energy and the RMSD values of
the C-a atoms of the protein are very close in value
among the three different MD runs; moreover, after the
initial relaxation, all of them keep a stable trend, at least
for the last 2 ns of MD simulations, indicating that a
relative stability has been reached. Figure 4b shows the
RMSD values computed for pranlukast atoms in the
three different MD trajectories. While the CI and CII
conformations show a similar constant trend during the
simulations, at the beginning of the MD run the CIII
shows RMSD values higher than CI and CII. These
values decrease to values similar to these of other two
conformations only in the last ns of the simulation. Fig-
ure 5 shows the relative free energy difference (ΔG
Binding) computed during MD simulations with the
a l g o r i t h mp r o v i d e db yt h eG r o m a c sa n a l y s i st o o l( s e e
Methods for more details). Plots report an estimation of
the relative ΔG Binding for the whole system, i.e. sol-
vent-receptor-ligand. As the ligand is the same for all
the three simulations, the reported values contain a con-
stant additional factor, i.e. the energy corresponding to
the free ligand in the solvent. Indeed, in our case, the
subtraction of the energetic components of the runs of
t h ef r e el i g a n di nt h es o l v e n tw o u l dn o th a v ea f f e c t e d
the ΔG values and hence the interpretation of the data
Figure 2 Macroscopic view of three best configurations of pranlukast docked to GPR17. The picture shows the three potential binding
poses (CI, CII and CIII) obtained for the antagonist pranlukast (stick representation) on GPR17 (cartoon representation), by means of docking
studies and 6 ns of molecular dynamic simulations. The chance of pranlukast to assume different and energetically comparable configurations, as
for CI, CII and CIII, it is probably due to the high flexibility of the molecule yielding its high conformational freedom.
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total energy profile as a function of time of the entire system membrane-receptor-ligand system during 6 ns of MD simulations, for the three
different pranlukast configurations, here indicated as CI (in black), CII (in red) and CIII (in green).
Figure 4 Comparison of the RMSD of C-a and ligand atoms of the MD simulations of the three docking configurations of pranlukast.
The plot a shows the RMSD of C-a atoms of the protein as a function of time obtained for the MD runs of CI (in black), CII (in red) and CIII (in
green). In panel b, the same colour are used to indicate the RMSD versus time of ligand atoms obtained for CI, CII and CIII simulations.
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trend was observed for CIII (lower ΔGB i n d i n gv a l u e s )
we wanted to focus our analysis on the conformation
globally giving the most effective docking. Standard
deviation for the three ΔG Binding profiles gave values
of 21.28, 10.09 and 22.12 kJ/mol, for CI, CII and CIII,
respectively. We noticed that, while displaying a higher
energetic profile, pranlukast CII conformation was char-
acterized by a more conserved and constant ΔG Binding
with respect to CI and CIII. Moreover, it also displayed
a smaller standard deviation: this was one of the reasons
why we decided to perform our analysis on this pranlu-
kast conformation. The binding energy computed by
means of docking tools, both before and after the MD
simulations varies from -13.21 to -14.93 kJ/mol for the
three conformations; thus a selection based merely on
the docking energy criteria is a bit risky, due to such a
subtle difference. The previous observations, together
with other evidence regarding the detail of the pose (see
below), suggest that the binding mode is optimal and
pranlukast is steadily docked into the pocket. A detailed
view of the principal polar or hydrophobic interactions
formed between pranlukast groups and residues within
the pocket for CI CII and CIII is briefly presented
below.
In CI, pranlukast assumes the more extended confor-
mation with respect to CII and CIII, where, conversely,
the molecules tended to fold into a closed conformation.
In fact, in CI, pranlukast spanned the helical bundle,
directing its tetrazole group toward the extracellular
space close to TM6, TM7 and EL2, and extending its
aromatic tail toward the inside region, parallel to the
elongation axes of the protein. The main polar
interactions formed by the tetrazole group within this
conformation involved residues Thr175, Asn176 (EL2),
Tyr251 (TM6) and Asn279 (TM7). The benzopyran and
the 4-oxo oxygen atoms of the chromone region were
hydrogen-bond (H-bond) acceptors for Tyr185 (EL2)
and Arg255 respectively, whereas the oxygen of the phe-
nylbutoxy-benzamide chain was H-bond acceptor for
Arg87 (TM2). The phenyl chromone ring was sur-
rounded by Tyr112 (TM3) and Tyr251 (TM6) at oppo-
site sides, suggesting a possible formation of π - π
interactions in both directions. Finally, the terminal phe-
nyl established a few hydrophobic interactions with resi-
dues belonging to TM2 and TM5, such as Val81, Ile84
and Met115. In CII, the tetrazole ring lied close to R255
and H252, at a distance compatible with the formation
of H-bonds. At present, we don’t have any clear-cut
information about the local protonation environment,
but it is reasonable to believe that pH conditions could
influence the acid-base equilibrium of the tetrazole
function, that could indeed manifest its deprotonated
state and express its acidic potential to form electro-
static interactions with the basic arginine and/or a pro-
tonated histidine. Other polar interactions concern the
keto group of the chromone, that could act as H-bond
acceptor for the hydroxyl groups of Tyr112 (TM3),
Tyr251 (TM6) and Tyr185 (EL2). Phenyl portions of
Tyr112 and Tyr251 can instead wrap the aromatic chro-
mone portion of pranlukast forming typical π - π inter-
actions. Aromatic portions of the residues Tyr116,
Tyr120, Phe201, Phe205, Phe244, Phe248 enclosed both
the terminal phenyl ring and the phenylbutoxy-benza-
mide group, giving rise to a big aromatic cluster, to
which also hydrophobic residues such as Val249 and
Figure 5 Free energy estimate of the binding of pranlukast. The free energy estimate of the binding of pranlukast for the 6 ns of MD
simulations performed for the three different docking configurations is reported in black for CI, in red for CII and in green for CIII.
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the MD trajectory, revealed that pranlukast within the
CII configuration, despite its stability, underwent con-
formational changes and two different conformations
were observed. In these two conformations the terminal
phenyl group can alternatively share the π-electron
cloud either with the phenyl ring of the phenylbutoxy-
benzamide group, or with the phenyl ring of the Phe201
residue, forming an intramolecular or an intermolecular
stacking interaction, respectively.
Also in CIII, pranlukast lied in a bent conformation, in
which the chromone portion held a position approxi-
mately perpendicular to the protein z axis rather than
parallel as in CII. Residues Gln183 (EL2), Tyr116 (TM3)
Ser196 (TM5) and His252 (TM6) are potential H-bond
donors/acceptors for tetrazole, whereas the benzamide
carboxyl could form H-bonds with the backbone atoms
of TM3 (Asn114-Tyr116). Within the presumptive
pocket, aromatic and hydrophobic interactions were
likely to be less defined than in CI and CII. An intramo-
lecular stacking interaction between the terminal and
the butoxy-benzamide phenyl was instead favoured,
since the aromatic tail of pranlukast remained in a
region of the protein close to the extracellular side and
to TM1 and TM2, where hydrophilic amino acids are
predominant.
In this respect, following the dynamical behavior of a
few water molecules derived from the X-ray structure of
bRh and present in our GPR17 model, it has been pre-
viously proposed that TM3 can divide the helical bundle
in two well distinct regions, each characterized by a dif-
ferent hydrophilic or hydrophobic profile [17]. TM4,
TM5 and TM6 form a first hydrophobic region where
highly conserved aromatic residues are predominant,
with the exception of the region immediately below the
interfaces with the extracellular space. Conversely, TM1,
TM2 and TM7 determine a second hydrophilic region
where all crystal water molecules tend to segregate,
weaving a network of polar interactions with the sur-
rounding residues that extends from the upper to the
lower side of the protein: in this way a sort of “polar
channel” is formed throughout the protein [17]. It
would be interesting to clarify if this polar channel is an
artefact of the model, or, alternatively takes part to sig-
nal transduction, as it has been demonstrated for the
proton pump in bacteriorhodopsin (bR) [66,67], thus
bridging extracellular events with the intracellular actors
of the transduction machinary.
Unfortunately, we couldn’t submit our results to a
convincing critical comparison with previous indepen-
dent data on other leukotriene-responding receptors,
because only few models of such receptors and/or
ligands have been developed so far, and the discussion
on their reliability is still open. For example, several
attempts for constructing a pharmacophoric model of
CysLT1 receptor antagonists based on structure-activity
relationships (SAR) studies have been reported, but they
a r en o tf u l l yc o n v i n c i n g ,s i n c en o n eo ft h e mi si nf u l l
accordance with the agreed features of the receptor.
One of the difficulties in the development of a reliable
3D pharmacophoric model for CysLT1 antagonists
resides in the flexibility of most antagonists. Further-
more, despite the fact that several antagonists share
identical structural elements with the agonists (and a
common binding site for agonists and antagonists has
been proposed), the existence of structural overlapping
between different classes of CysLT receptor antagonists
and/or agonists is still debatable [68]. Based on quantita-
tive SAR studies (QSAR), an hypothetical computational
model of CysLT1 pocket has been built using almost
rigid leukotriene antagonists as template; an arginine
residue is incorporated into the preliminary model as an
interaction site for the acidic moieties of antagonists
[68]. This revealed additional interactions between the
guanidine group and the nitrogen atoms of quinoline-
containing CysLT1 antagonists. In some cases, the argi-
nine residue could eventually interact also with π-clouds
of phenyl moieties of CysLT1 antagonists. These data
suggested that a pharmacophoric model based on struc-
tural similarity of agonists and antagonists may not be
valid, and that antagonists do not necessarily bind to the
same site or in the same manner as agonists. In the
same model, the different alignment between pranlukast
and montelukast suggested the presence of an additional
pocket in the binding site for CysLT1 antagonists.
Recently, a model of LTE4 complexed with P2Y12 recep-
tors has been proposed, on the basis of in silico screen-
ing data, combined with intracellular calcium
concentration measurements in CHO cells stably
expressing a P2Y12-G16a fusion protein [11]. It
has been demonstrated that, in addition to adenine
nucleotides, the P2Y12 receptor, can respond to 5-phos-
phoribosyl 1-pyrophosphate (PRPP) and LTE4. For the
LTE4-P2Y12 complex, it has been hypothesized that the
1-carboxylic acid and the 5-hydroxyl group of LTE4
interacted with Glu263 of TM6; the amino acid portion
of cysteinyl group interacted with Leu284 of TM7, and
the carboxylic acid with Ser101 of TM3. In conclusion,
it is evident that additional advances need to be done in
order to understand the cysteinyl-LTs binding modal-
ities and to find a unifying theory that reconciles all the
findings reported so far.
On this basis, we focused our subsequent experiments
on CII, where the tetrazole group of pranlukast is close
to the H-X-X-R motif, and the phenyl rings are placed
into a hydrophobic subpocket, that is highly conserved
a m o n gG P C R s :t h i si si nf a c tb e l i e v e dt ob eac o m m o n
ancestral recognition target for this receptor superfamily
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Phe244 and a triplet of embedded tyrosines belonging to
TM3 held the aromatic portions of pranlukast. A
detailed view of CII is showed in Figure 6. Several other
r e a s o n sh a v el e du st of o c u so nt h i sc o n f i g u r a t i o n .T h e
first reason is that, according to this potential model,
nucleotidic ligands and pranlukast would target the
same arginine residue, providing an interesting issue to
investigate. As cited before, an arginine residue has also
been proposed as a partner for tetrazole or acidic func-
tions of CysLT antagonists by Zwaagstra and coworkers,
because of the favourable electrostatic potential of the
guanidine group, of the ability to form multiple H-
bonds in addition to the electrostatic ones, and finally
because of the wide delocalization of the electronic-
clouds of the guanidinium functional group. Figure 7
shows the superimposition of UDP with the three differ-
ent poses of pranlukast within the putative GPR17 bind-
ing pockets identified by means of our docking and MD
studies. Among the three docking poses obtained for
pranlukast, only configuration CII (in green) is likely to
share the target residue R255 with UDP (in red). In fact,
while in the CII conformation pranlukast accommodates
the tetrazole ring in proximity to the R255 residue,
close to the phosphate chain of UDP (see dotted lines
identifying the potential interactions), in the CI and CIII
conformations, pranlukast is not likely to form interac-
tions with the same residue. Moreover, the tetrazole
group of pranlukast, that is directly connected to a rigid
electron-rich system, recalls some structural elements of
the 2-tetra-phenyl-containing subclass of the so called
“priviledged structures”. The latter are indeed selected
scaffolds that are able to provide high-affinity ligands for
more than one type of receptors, targeting common
conserved motifs of the GPCR superfamily. Such struc-
tural motifs have been successfully used by many phar-
maceutical companies to design “universal”
pharmacophores and to synthesize combinatorial
libraries, which are subsequently tested against novel
GPCR targets, in an attempt to find lead compounds. In
particular, for the 2-tetrazol-phenyl-containing subclass,
it has been proposed that the phenyl moiety can be
accommodated in a conserved aromatic TM subpocket
formed by Phe6.44, Phe6.48 and Trp5.47 (TM5 and
Figure 6 Model of the pranlukast conformation CII. Model of
the complex formed by pranlukast and GPR17 after 6 ns of
conventional MD simulation. Pranlukast is displayed in orange
within the detailed binding pocket.
Figure 7 Superimposition of UDP and pranlukast within the
putative GPR17 binding pockets. The picture shows the
superimposition of UDP (in red) with the three docking poses of
pranlukast (CI, in blue; CII, in green; CIII, in gray). For each
simulation, the correspondent target residue R255, here highlighted
with arrows, is reported in the same colors of either UDP or
pranlukast. The hypothetical interactions between R255 and ligands
are represented by white dotted lines.
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positioned at positions 5.43, 6.52 and 5.42 or 6.55 [69].
In our GPR17-pranlukast CII complex model we
observed a strong similarity with the interaction pattern
predicted for priviledged structures: we therefore per-
formed SMD study on this pranlukast configuration
rather that on the other two. Finally, it is know that the
key residue in the binding and/or activation mechanism
of several GPCRs is a basic residue, frequently an argi-
nine [70-75]: on this basis, we focused our attention on
the Arg255 present on GPR17 that thus became an
attractive target for the present study.
Steered MD simulations
SMD experiments on GPR17-WT model, were set start-
ing from the last minimized frame of the MD trajectory
of the ligands UDP and pranlukast (CII). The residue
Arg255 was then mutated to isoleucine, choosing the
energetically favoured isoleucine rotamer among the
ones proposed by the sequence mutation tool of the
software Moe http://www.chemcomp.com. The R255I
mutant model of GPR17 was thus obtained. Preliminary
SMD experiments were performed choosing various
pulling rates and pulling force entities, in order to vali-
date the method on the two receptors. SMD experi-
ments were then performed in parallel for both the WT
and the R255I mutant model complexed with the
ligands; then the mechanical resistance offered by the
ligands through different unbinding pathways was mea-
sured. During the outgoing pathway from its pocket, the
resistance yielded by the ligands was registered: both
sterical factors and non-bonded interactions contributed
to the observed peaks of force in the pulling steps. Here,
for the interpretation of results, force peaks risen from
SMD trajectory have been scaled to energetic values
(kcal/mol) (see Methods for details). All the trial simula-
tions provided comparable energetic profiles, although
the elapsed time between similar events is different, as it
depended on the pulling force/rate combinations. The
analysis for the pulling experiments was focused on the
results obtained using the following parameters: pulling
rate 
v = 0.004 nm/ps and constant force k = 2000 kJ/
mol nm
2 for a total duration of 1000 ps: this has proved
to be the more equilibrate choice. As mentioned before,
the SMD experiments were performed for both the WT
and the R255I model on the CII pranlukast configura-
tion. Here, the tetrazole group of pranlukast was close
to position 6.55 on TM6, and the phenyl rings were
embedded into the highly conserved aromatic/hydro-
phobic pocket enclosed among Phe201, Phe205, Phe244
and a triplet of tyrosines belonging to TM3. In Figure 8,
the SMD unbinding trajectory of pranlukast from the
WT and R255I receptors are compared. Panel a shows
the pulling energy plot, computed for the WT (in red)
and the R255I (in black) receptor models, respectively.
No significant differences in terms of maximum value of
energy were found comparing the two energetic profile
for the two models; moreover, both energy profiles had
values significantly lower than the ones observed for the
unbinding of UDP from the WT receptor. This first
observation on the energy involved in the unbinding
suggests that the mutation of Arg255 did not definitely
affect the binding of pranlukast to its binding pocket.
The comparison of the SMD for the WT and the R255I
receptor model (in panel a and b the WT and the R255I
simulations are reported in red and black, respectively),
shows only one relevant energetic peak in the case of
R255I: this happened in correspondence with the transi-
tion of the ligand through the plug. This is highlighted
also by the plot reported in panel b, where the displace-
ment of pranlukast in the two simulations is reported.
The pattern of the main interactions, computed as dis-
tances, between atoms of the pair of functional group
involved in the bonds formation as a function of time,
was similar for both the WT (panel c) and the R255I
(panel b) receptor models. For the WT simulations, the
interaction between Arg255 (in black) and tetrazole
group persisted up to 440 ps, when also the interaction
His252-tetrazole was broken (in magenta). Only a small
peak corresponding to this event was found in the pull-
ing energy plot for the WT simulation, as further confir-
mation that probably the mutation of Arg255 doesn’t
significantly influence the binding of pranlukast to
GPR17. This suggests that the aromatic residues play
instead a key role in the recognition of pranlukast. Sev-
eral π - π interactions involving phenyl function of
pranlukast and aromatic residues within the pocket were
indeed observed for both the WT and the R255I recep-
tor model, as shown in panel c and d, respectively.
Among these, residues Tyr112, Tyr116, Tyr120, Tyr251,
Phe201, Phe205, Phe244 and Phe244 are likely to
accommodate pranlukast, thus representing a potential
binding pocket for the antagonist. Moreover, analysis of
the SMD trajectory for both WT and R255I receptors
showed that, despite the constraints imposed by the
conserved disulphide bond Cys104-Cys181 linking EL2
to TM3, during the traction of the ligands out of the
receptor EL2 moved toward the extracellular space
showing an hinge movement allowing the opening of
the crevice on the top of the receptor. Measurement of
the distance between the C-a atoms of the outmost resi-
dues in both the open and closed forms of EL2 yielded
to a maximum span of 6.6 Å, as shown in Figure 9. For
other GPCRs, this hinge movement, that highlights the
very high flexibility of EL2, has been already associated
with the activation mechanism, among which the 5-
HT4A the complement factor 5a receptor C5a, the M3
and the related P2Y6 receptors [76-79].
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Here, we present a computational study of a bRh-based
homology model of the human GPR17 receptor, that
extends our previous MD analysis of the purinergic
component of this receptor and highlights some intri-
guing aspects of its dualistic nature. While this work
was already in progress, the crystal structures of the first
human GPCRs ad of additional receptors form other
species have been published [22-28]. It was therefore
critical to verify that the basic structural assumptions
previously made by modeling GPR17 on bRh were still
true at the light of the new published structures. To do
so, we superimposed the C-a atoms of the A2AR, the
b2AR-Fab, the b2AR-T4, the b2AR(E122W)-T4 and the
b1-AR to GPR17 and to bRh.
The obtained RMSD values varied from 1.955 to 2.867
Å, a range which is not significantly different from that
obtained by superimposition of the same structures to
Figure 8 Forced unbinding profile of pranlukast. Panel a and b compare the unbinding simulations of pranlukast from the WT (in red) and
the R255I (in black) receptor models: panel a shows the work developed to unbind pranlukast; panel b shows the displacement of the COM of
the ligand from its starting position. Panel c and d show the distances between groups of atoms of the ligand that form polar or hydrophobic
interactions with atoms of the WT or the R255I models, respectively.
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sented here have general value and actually give informa-
tion on the putative 3D structure of this new receptor.
To further support the validity of our approach, in a
recent publication, Costanzi was able to reproduce the
docking pose of the ligand carazolol in two bRh-based
homology models of the b2AR. Comparison of the
homology models with the X-ray structures of the b2AR
elegantly demonstrated that realistic GPCR structures
can be obtained through accurate modeling based on the
bRh structure [80]. Furthermore, bRh-based homology
models for other related receptors, i.e. the P2Y2 receptor,
are still being proposed to exploit the most favourable
sequence similarity with this template bRh with respect
t ot h es e q u e n c eo ft h en e w l ys o l v e dG P C R s[ 8 1 ] .T h i s
confirms that, in spite of their low sequence identity/
similarity, all GPCRs share a common scaffold and sup-
ports the role of this approach as a powerful tool for the
drug discovery process. Our data are also in line with
some of the conclusions made for other GPCRs on the
basis of these recently published crystal structures. For
example, it has been reported that, in contrast to the b-
adrenergic ligands and retinal, the A2ARa n t a g o n i s t
ZM241385 exhibits a significantly different orientation
within the TM bundle. Interestingly, the bound A2AR
ligand, while interacting with helices, gets also in contact
with EL2 and EL3. In a similar way, the involvement of
EL2 in ligand binding to GPR17 was consistently pre-
dicted also by our SMD study, thus suggesting that this
may represent a common characteristic of some specific
GPCRs subgroups. This peculiarity adds diversity to the
class A family of GPCRs and may play an important role
in driving receptor selectivity.
O u rs p e c i f i cc h a l l e n g ei nt h ep r e s e n ts t u d yh a sb e e n
to use MD and SMD experiments as guide to the design
of in silico site-directed mutagenesis experiments that,
combined with ligand affinity measurements and hope-
fully further structural informations, could contribute to
the design of new selective therapeutics for targeting
GPR17. We focused our attention on Arg255, that has
been proposed to play a crucial role in binding of other
P2Y receptors to their nucleotide ligands [35-40], and
substituted this Arg with Ile (R255I). Our SMD simula-
tions, showing that the energy required to unbind pran-
lukast UDP was not significantly different between the
WT receptor model and the mutated R255I, highlights
the role of the basic residue Arg255 in the binding to
nucleotides. No significant differences between the WT
and the mutated receptor were instead found for the
unbinding of the leukotrienic ligand pranlukast from
GPR17; the magnitude of the forces used was also equal
to the one used to unbind UDP from the R255I mutant
receptor. Furthermore, pulling forces developed to break
polar and aromatic interactions of pranlukast were com-
parable, suggesting that aromatic interactions are likely
to play a predominant role in the recognition of pranlu-
kast. Compared with our previous data obtained simu-
lating the forced unbinding of UDP, the magnitude of
the energy used to dissociate pranlukast form both the
WT and the R255I receptor models was also near to the
one used to unbind UDP from the R255I mutant recep-
tor [82]. MD simulations thus suggest that the mutation
of Arg255, while influences the binding of nucleotides
to GPR17, does not affect the binding of pranlukast,
indicating that two different subsites are present on
GPR17 and that the intermolecular interaction networks
with the ligands are different between UDP and
pranlukast.
The existence of two different binding sites on this
receptor, regardless of the agonist and antagonist nature
of the ligands, is also consistent with the intrinsic differ-
ence in the chemical structure of the two classes of
unrelated purinergic and leukotrienic ligands. Moreover,
this hypothesis is also supported by the peculiar organi-
zation of the TM crevice, that, in GPR17, identifies two
well defined areas with different hydrophilic/phobic sur-
face profiles.
At present, the mechanism of activation and inactiva-
tion of the receptor is unknown, but some general
hypothesis about the most probable target residues can
be formulated, based on the present computational data.
Regarding the putative nucleotide binding site, in GPR17,
in agreement with the other members of the P2Y recep-
tor family, the same binding cavity seems to be shared by
purinergic agonists and antagonists, at least for small
ligands. As described in our previous work [17], the
antagonist cangrelor, due to its long aliphatic branches
that depart from the nucleobase, can reach regions of the
protein that are unaccessible to other nucleotide-derived
Figure 9 EL2 dynamical behaviour.R e p r e s e n t a t i v ef r a m e so ft h e
open and closed form of EL2, extracted from the SMD simulation,
are reported in green and red, respectively. The picture shows a
detailed view of the hinge movement of the loop that exhibits an
extension up to 6.6 Å.
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GPR17, the characterization of the binding site is even
more uncertain, due to the flexible nature of the ligands
for which the identification of the docked conformation
to the CysLT1 and CysLT2 receptors has not been yet
successful. Nevertheless, our data highlight the impor-
tance of the conserved aromatic/hydrophobic cluster for
the recognition of pranlukast. Further investigations are
needed to unveil whether this feature is shared by both
agonist and antagonists. Finally, the hypothesis that two
distinct binding sites, one for nucleotides and the other
one leukotrienes, are present on GPR17 is in accordance
with our previous experimental cross-antagonism data. It
has been indeed demonstrated that, in 1321N1 cells het-
erologously expressing hGPR17, blockade of the cystei-
nyl-LT binding site with the CysLT antagonists
montelukast or pranlukast did not abolish the response
to uracil derivatives. In a similar way, blockade of the
nucleotide binding site with either cangrelor or MRS2179
still permitted the response to LTD4. The computational
approach presented here, with the support of other
experimental strategies designed to confirm our hypoth-
esis and to improve our computational model, could aid
to elucidate, step by step, the molecular mechanisms at
the basis of ligands-mediated GPR17 activation/
inactivation.
With the present study, we also aimed at getting some
hints on the overall mechanism of ligand recognition, i.
e. not only on the role of the single amino acid residues,
but also on the role played by the conformational rear-
rangement and mobility of protein domains, such as
helices and loops. In fact, loop regions are currently
deemed to be involved in the binding of large molecular
weight ligands (i.e., peptides), while their role in the
recognition of small molecules-responding GPCRs
remains largely unresolved. It has been proposed that
EL2 does not only provide a docking surface for the
recognition mechanism, but could also act as a flexible
“gatekeeper” in the binding of both allosteric and
orthosteric GPCR ligands [83]. In agreement with this
hypothesis, our SMD simulations unmasked the flexibil-
ity of EL2, that was not evident with conventional MD
simulations run in the same time scale. Globally, these
data advance our knowledge on the structure of the new
hybrid receptor GPR17 and will eventually contribute to
the design of “dual” ligands for this new target of high
therapeutic relevance.
Methods
Preparation of the model of the membrane-GPR17-ligand
system
A previously published rhodopsin-based homology
model of the human GPR17 receptor embedded in a
hydrated dipalmitoyl-phosphatidyl-choline (DPPC)
bilayer and refined by means of MD was used as starting
point for both the conventional MD and the SMD stu-
dies [17]. Docking studies and MD simulations of pran-
lukast were indeed performed on the same stable 3D
structure of GPR17 coming from the 10 ns MD simula-
tions and already used for the previous docking studies
of GPR17 ligands. Locally minimized structure of the
ligands docked into the membrane-receptor complex
subjected to conventional MD simulations, were used as
starting points for SMD experiments. The structure of
the GPR17-UDP complex was taken form the already
published model [17].
Molecular dynamics simulations
The structure of GPR17 extracted from the 10 ns of MD
simulation was submitted to a binding-cavity search
using the Sitefinder tool included in the Delos package.
Pranlukast was then docked into the suggested cavity
using the docking tool included in the AutoDock 3.0
package [84], applying the genetic algorithm procedure
to semiflexible docking module. AutoDock tools (ADT)
were used to prepare the ligand and protein. A grid box
w i t ht h ed i m e n s i o n s6 8×7 6×7 0p o i n t sf o rt h ex, y
and z axis was constructed with grid points separated by
0.375 Å. The the population size was set to 50 and the
rest of the parameters were taken as default according
to the manufacturer’s instructions. Among the docking
configurations of proposed for pranlukast by AutoDock
the three best energy scoring poses were chosen for
further investigations by means of MD simulations.
Pranlukast docked in the three configurations, together
with the sidechains of the residues within 4.5 Å dis-
tance, was locally minimized, before starting MD run.
Ligands topology for the MD runs were obtained from
the automatic server PRODRG [85], using the standard
Gromacs forcefield. The systems membrane-receptor-
ligand was prepared for the MD simulations using a
stepwise protocol. First, the systems were gradually
minimized via the steepest descent allowing the various
components to move individually with the following
order: solvent and lipids, sidechains, the whole systems.
The conjugate gradient method was then applied to
improve the energy content of the system. The three
ligand-receptor-membrane complexes were heated to
the simulation temperature of 310 K in 300 ps and the
three MD runs of 6 ns each were performed using the
general conditions defined for this study and described
in the “Computational details” subsection. The free
energy calculations for the ligand-receptor complexes
during MD were performed using a linear interaction
energy (LIE)-based algorithm, as implemented in the
MD software Gromacs. Using this method, the free
energy is computed as an estimation of the difference in
Gibbs free energy between two thermodynamic states of
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bound ligand in solution minus the free energy of the
macromolecule in solution plus the free ligand in solu-
tion at standard concentrations, all at the same tempera-
ture and pressure [86]. In our case, for the comparison
of MD simulations of pranlukast bound to GPR17, con-
sidering that our MD runs share the same ligand (and
thus the same hypothetical simulation of the free ligand
solution), we only computed the relative ΔGB i n d i n g
between the three simulations of the complexes.
Steered molecular dynamics simulations
To induce the unbinding of ligands from the receptor,
an external force was applied to center of mass (COM)
of the ligand, simulating retracting cantilever directed
along an imposed vector (see below). Due to action-
reaction principle, the spring acts as a sensor of all
interacting processes along the selected exit pathway.
The elastic force is proportional to the spring elongation
relative to its equilibrium position, and it is given by the
expression: 
F = k( 
v t - 
x ), where 
v t - 
x is the displa-
cement of the restrained atom with respect to its origi-
nal position; t is time elapsed from the beginning of the
simulation; 
v = 0.004 nm/ps corresponds to the velo-
city of the retracting cantilever and k = 2000 kJ/mol nm
2
is its force constant. In order to have a zero extra force at
starting time, when the spring should be relaxed, displa-
cement was set to 0 for time t = 0. For the interpretation
of the results we converted the registered pulling force in
energy values, by applying the following expression: E =

v ( 
v t - 
x ). For the comparison of the unbinding pro-
cesses of the agonist and the antagonists the mentioned
combination for 
v and k was chosen among different
values used in a previous series of simulations performed
using combination of 
v values (0.001-0.01 nm/ps) and
k values (2000-5000 kJ/mol nm
2): the value of 
v was
chosen so that the complete unbinding of the ligands
occurs within 1 ns for each SMD simulation, that seemed
to us a good compromise between in saving computa-
tional time and register atomistic events. The value of
k w a sc h o s e nt oo b t a i nas t i f fs p r i n gi nad r i f tr e g i m e .
The vector along which ligands were pulled apart was
imposed for both ligands parallel to the z axis of the pro-
tein, and also parallel to the principal axis of the mem-
brane that, for a GPCR, is likely to correspond to the
only exit path possible for a bound ligand. To define the
exact values of the components (versors) of the pulling
vector, an hypothetical end point of the unbinding path-
way for both ligands was chosen by superimposition of
the two ligands in the extracellular solvated environment.
Then, by means of a homemade script, we computed
the values of the three versors defining the direction
of the hypothetical vector along the z axis and connecting
the COM of each ligand in the starting position and the
COM of the ligand in the final position. To ensure that
velocity kept a constant value for the whole simulation, a
combination of the x, y and z versors was then computed
in a such way that they would give a unit vector.
Computational details
All the simulations were run on a Linux cluster Blade
with Xeon processors. All the minimization steps, MD,
SMD simulations and concerning analysis were curried
out using the Gromacs 3.3 package [86,87]. All the MD
and SMD runs were performed using the Gromacs force
field, modified by all the parameters necessary for the
description of each component and their reciprocal
interactions, based on manifacturer’s instructions; the
periodic boundary conditions were applied in all three x,
y and z dimensions. The isothermal isobaric NPT
ensemble (constant number of particles, pressure and
temperature) was applied. Solvent (water molecules and
chloride ions) and non-solvent (lipids, protein and
ligands) component of the system was separately
coupled to a temperature bath at 310 K, with a coupling
constant τt of 0.1 ps. The pressure coupling was set as
independent in the x and y directions (semi isotropic
coupling), with a constant pressure of 1 bar and a cou-
pling constant τp of 1 ps. A 2 fs time step was used for
the integration of the equations of motions and all bond
distances involving hydrogen atoms were constrained
using LINCS [88]. Configurations were saved for every
1 ps for analysis. The analysis of the trajectories were
computed with the specific Gromacs tools.
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